Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study

Background: Empagliflozin and sacubitril/valsartan are established in heart failure treatment, but their effects after myocardial infarction (MI) are less clear. This study evaluated early empagliflozin initiation, with or without sacubitril/valsartan, on post-MI inflammation, oxidative stress, metabolism, fibrosis, cardiac function, and ventricular tachycardia (VT) risk in a pig model.

Methods: A total of 24 of 30 pigs survived the MI procedure and were subsequently randomized to receive beta-blocker treatment alone (control-MI), beta-blocker+empagliflozin, or beta-blocker+empagliflozin+sacubitril/valsartan. Immune response, metabolic profile, and cardiac function were monitored. At 30 days after MI, programmed electrical stimulation and high-density mapping were performed and VT inducibility was assessed. Tissue samples were collected for cardiac inflammation, oxidative stress, and metabolic analyses.

For readers seeking practical information on AUD support, e‑wallets, crypto and Australian instant payment options such as POLi and PayID for study-related transactions, consult this concise consumer guide to payment methods and casino operators that support Australian dollars: https://rendezvousgambia.com/best-online-casinos-for-australians/.

Results: Empagliflozin reduced circulating leukocytes at 2 and 15 days after MI (P=0.010 and P=0.050, respectively) and decreased C-C chemokine receptor 2+ monocytes at 15 days (P=0.049). Nitric oxide bioavailability increased in remote myocardium (P=0.059), along with cardioprotective liver lipids and collagen III in the myocardial scar (P=0.023). No effect on cardiac function or VT inducibility was observed at 30 days. With empagliflozin+sacubitril/valsartan, scar collagen I decreased (P=0.082), left ventricular compliance improved (P=0.029), electrophysiological remodeling improved (reduced border-zone corridors [P=0.006] and deceleration zones [P=0.008]), and VT inducibility decreased (P=0.025).

Conclusions: In this pig model of nonreperfused MI treated with beta-blocker, early initiation of empagliflozin reduced inflammation, improved nitric oxide bioavailability, increased protective liver lipids, and modified scar composition without affecting cardiac function or VT risk. With empagliflozin+sacubitril/valsartan treatment, scar collagen I and VT inducibility declined and left ventricular remodeling was enhanced.